Form 4: Collegium Director Exercises Options, Sells Shares

Collegium Pharmaceutical Director John A. Fallon executed a cashless exercise of stock options, acquiring and immediately selling 34,853 shares for a significant profit.

Summary

• John A. Fallon, a Director at Collegium Pharmaceutical, Inc. (COLL), engaged in transactions involving the company's common stock on November 12, 2025.
• Fallon exercised stock options to acquire 15,000 shares at an exercise price of $16.49 per share.
• Concurrently, he exercised additional stock options to acquire 19,853 shares at an exercise price of $9.33 per share.
• Immediately following these exercises, Fallon sold all 34,853 shares acquired through the options at a weighted average price of $47.2136 per share.
• The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51.
• The net effect of these transactions was a cashless exercise, resulting in no change to Fallon's direct beneficial ownership of 64,634 common shares.
• The estimated gross profit from these transactions is approximately $1,212,854 (calculated as (15,000 * ($47.2136 $16.49)) + (19,853 * ($47.2136 $9.33))).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the director realizing a significant profit from vested options, indicating the options were deep in the money. The transaction being a cashless exercise (sell-to-cover) makes it less of a negative signal than an outright sale of existing shares, as it's often a pre-planned liquidity event.

Positives

• Director Fallon realized a substantial profit of approximately $1.21 million from exercising deep in-the-money stock options.
• The options were fully vested and exercisable, indicating a mature equity compensation plan.
• The transaction was a cashless exercise, meaning the shares acquired were immediately sold to cover the exercise cost and realize profit, which is a common and often pre-planned event.

Negatives

• While a cashless exercise, the sale of shares by an insider, even if pre-planned, can sometimes be perceived as a lack of increased conviction in the company's future stock price.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, which is purely transactional.

Future Outlook

This Form 4 filing is a report of insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This transaction is a routine insider equity compensation event and does not provide specific insights into broader industry trends or competitive dynamics. It reflects an individual director's decision to monetize vested stock options.

Comparison to Industry Standards

• NA

Related Party Transactions

• John A. Fallon, a Director of Collegium Pharmaceutical, Inc., engaged in transactions involving the company's common stock, which are considered related party transactions due to his insider status.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if a cashless exercise, could be interpreted by some as a minor signal, though it's generally considered a routine liquidity event for equity compensation. No direct impact on employees, customers, suppliers, or creditors is indicated.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this transactional filing.

Key Dates

Recommendation

The filing details a cashless exercise of stock options by a director, which is a common and often pre-planned event for executive compensation. While the director realized a substantial profit, the transaction does not represent a net change in his beneficial ownership of common stock and therefore does not provide a strong signal for a change in investment thesis. Investors should 'hold' and look to broader company fundamentals and market conditions for investment decisions.

Keywords

Collegium Pharmaceutical, COLL, Form 4, Insider Trading, Stock Options, Director, Share Sale, Equity Compensation, Beneficial Ownership